Evofem will work with WomanCare Global and future partners to make Amphora available and affordable to women in the developing world, upon successful completion of trials and regulatory approval. While prospective pharmaceutical company acquirers will likely be most interested in Amphora's potential in US and European markets, Evofem intends to negotiate with possible acquirers to carve out rights to Amphora distribution in less developed countries in Africa, Latin American, and Asia. In conjunction with non-profit supply chain specialists, WomanCare Global and Evofem will seek to ensure that any acquisition of Amphora will contain a plan for large-scale access to Amphora in the developing world, in order to meet its social mission.
Evofem and WomanCare Global seek to partner with pharmaceutical companies that share a vision not just for global commercial success for these two products, but also for widespread access to these products in the developing world. While Evofem brings skills in product design and development, WomanCare Global brings know-how in reaching women and girls in more than 100 countries, including those in Africa and other developing markets.
Evofem will begin discussions with potential pharmaceutical company acquirers in September 2013. Evofem will meet with pharmaceutical executives and demonstrate models showing profit and losses by region and country. With support from CGI throughout 2013, Evofem will make the case to potential acquirers for significant distribution in unprofitable markets.
More than 200 million women in the developing world lack access to modern contraceptives, and therefore have no means of determining whether and when they will have children. Even in places where some contraceptive methods are available, there are very few choices to meet women's varying needs. Many women want methods that are non-hormonal (to avoid side effects) and that they themselves control (rather than a health provider or a partner). Others want methods that are short-acting and used on-demand. While spermicidal products have fit these needs in the past, most contain non-oxynol 9, a controversial chemical which the FDA recently ruled can actually increase a woman's risk of contracting a sexually transmitted infection (STI) in certain cases. What is needed is a new method to meet women's needs: a product that is non-hormonal, used on-demand, woman-controlled, and affordable.
Evofem LLC, a product development company with a social mission of improving the lives of women and girls, has developed a contraceptive gel to fill this gap in the contraceptive method mix. 'Amphora' gel, as the product is known, is expected to conclude a large Phase 3 clinical trial soon. In anticipation of a successful outcome to the trial, Evofem has begun discussions with various pharmaceutical companies that wish to acquire the product. Evofem hopes to negotiate a partnership with a pharmaceutical company that will include a sizeable element of distribution of Amphora in the developing world, and not just in more developed markets in North America and Europe.
Evofem is seeking partnerships with pharmaceutical companies to commercialize Amphora contraceptive gel globally. In all partnership discussions, Evofem and WomanCare Global will work to identify a role for Amphora in developing markets.